Showing 3801-3810 of 8742 results for "".
- AAD Honors Dr. Ginette Okoye with National Patient Care Hero Award for COVID-19 Testing Workhttps://practicaldermatology.com/news/aad-honors-dr-ginette-okoye-with-national-patient-care-hero-award-for-covid-19-testing-work/2460729/The American Academy of Dermatology (AAD) named board-certified dermatologist Ginette Okoye, MD, FAAD a Patient Care Hero for establishing a dedicated COVID-19 community testing site in a historically underserved neighborhood in northeast Washington, DC. Amid the initial surge in COVID-
- Kenneth J. Tomecki, MD, FAAD is New President of the AADhttps://practicaldermatology.com/news/kenneth-j-tomecki-md-faad-is-new-president-of-the-aad/2460723/Kenneth J. Tomecki, MD, FAAD is now president of the American Academy of Dermatology (AAD). During his one-year term, Dr. Tomecki will lead the world’s largest dermatologic society, representing more than 20,000 physicians specializing
- NRS Launches Updated Version of "Understanding Rosacea" for Patientshttps://practicaldermatology.com/news/nrs-launches-updated-version-of-understanding-rosacea-for-patients/2460721/The National Rosacea Society has updated its most popular educational booklet. The new edition of “Understanding Rosacea” incorporates the updated standard classification and pathophysiology of rosacea, developed by a consensus committee and review panel of 28 rosacea experts worldwid
- AccuTec Blades: New Catalog Launches AccuThrive Brandhttps://practicaldermatology.com/news/accutec-blades-new-catalog-launches-accuthrive-brand/2460719/Introducing the newAccuThrive® medical brand, AccuTec Blades® Inc. has published its 2021 histology catalog. The 2021 AccuThrive blades portfolio highlights
- Dr. Adam Friedman Named Chair of Dermatology at George Washington Universityhttps://practicaldermatology.com/news/dr-adam-friedman-named-chair-of-dermatology-at-george-washington-university/2460718/Adam Friedman, MD has been
- Dr. Roy Geronemus Named CEO of NavaDermhttps://practicaldermatology.com/news/dr-roy-geronemus-named-ceo-of-navaderm/2460715/New York City dermatologist Roy Geronemus, MD is NavaDerm Partners’ new Chief Executive Officer. Dr. Geronemus graduated from Harvard University and pursued his medical education at the University of Miami School of Medicine where he is a member of the school's Alumni Hal
- Launching from Nutrafol: New Pro-Strength Boostershttps://practicaldermatology.com/news/launching-from-nutrafol-new-pro-strength-boosters/2460713/New professional-strength boosters from Nutrafol extend the popular nutraceutical line, providing physicians the opportunity to individualize recommendations for each patient’s specific hair health needs. Hairbiotic MD is a professional-strength
- New from Solta: Meet the Next Generation Clear + Brilliant Laserhttps://practicaldermatology.com/news/new-from-solta-meet-the-next-generation-clear-brilliant-laser/2460711/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- Advanced Aesthetic Technologies, Inc.’s Algeness Named Top Finalist in Terra2 Solution Skin Health Innovation Competitionhttps://practicaldermatology.com/news/advanced-aesthetic-technologies-incs-algeness-named-top-finalist-in-terra2-solution-skin-health-innovation-competition/2460708/Advanced Aesthetic Technologies, Inc. (AAT) and Algeness are finalists in the recent Terra2 Solutions Skin Health Innovation Competition. Algeness is a patented family of fully resorbable injectable gel implant dermal fillers that are 100% natural and based on purified agarose with
- New Research Highlights Global Challenge of Leprosyhttps://practicaldermatology.com/news/new-research-highlights-global-challenge-of-leprosy/2460706/The global problem of leprosy may be bigger than recognized, new research suggests. In fact, 40 million individuals around the world require preventive treatment in order to reduce the incidence of leprosy or Hansen’s Disease by 90% in 22 years. The new research by